Does Iowa Medicaid Cover Wegovy? One Form, Three Routes, No Weight Loss

No. Iowa Medicaid will not pay for Wegovy to treat weight alone: its drug list marks Wegovy and Zepbound “weight loss indication not covered,” and state rule bars payment for weight-loss drugs.^[1][4] As of November 2026, both are preferred drugs that a prior authorization can approve for three other uses: Wegovy to lower heart risk in adults with cardiovascular disease, Wegovy for the liver disease MASH, and Zepbound for moderate to severe sleep apnea.^[3]

Does Iowa Medicaid cover Wegovy for weight loss?

No. Iowa’s administrative code lists drugs used for weight loss, weight gain or anorexia among the drugs it will not pay for.^[4] The prior authorization criteria repeat it for the diabetes drugs (requests for weight loss “will be denied”) and for Wegovy and Zepbound, where the form says payment for weight loss as an excluded use will be refused.^[2][3] Under federal law, states may make that choice.^[9] Our explainer on how Medicaid handles Ozempic and Wegovy covers the federal background.

Your managed care plan does not change the rule. Iowa Total Care, one of the state’s plans, says it follows the state drug list to decide which drugs are covered and which need prior authorization.^[5] That job is moving to the state. Starting December 1, 2026, Iowa Medicaid will run the pharmacy benefit for managed care members itself, and Optum Rx, its pharmacy vendor, will review all outpatient pharmacy prior authorizations.^[15] Plans accept pharmacy requests until 4:00 p.m. Central on November 30, 2026, and Optum Rx will honor an active plan approval for as long as it lasts.^[15]

What does Iowa Medicaid cover instead?

The diabetes route is lighter than in many states. A preferred GLP-1 for type 2 diabetes needs a current A1C result, with no stated metformin trial, and Mounjaro is preferred alongside Ozempic.^[1][2] A non-preferred diabetes drug, such as generic liraglutide, requires failed trials of at least three preferred drugs from three classes.^[2]

Will Iowa Medicaid cover Wegovy for heart disease?

Yes, and Iowa reads “established cardiovascular disease” broadly. The form accepts coronary artery disease, including angina or a past heart attack; stroke or a transient ischemic attack; peripheral artery disease; heart failure; atrial fibrillation and other rhythm problems; valve disease; congenital heart disease; cardiomyopathy; aortic aneurysm or dissection; and a past deep vein clot or pulmonary embolism.^[3] The adult must have a BMI of at least 27 measured within six months, and the prescriber confirms that standard heart care has been reviewed.^[3]

That is wider than the trial behind the label. SELECT enrolled people 45 and older with a past heart attack, stroke or symptomatic artery disease, a BMI from 27 up, and no diabetes.^[12] The label itself says only “established” heart disease with obesity or overweight, and Iowa’s form follows the label, setting the minimum age at 18 rather than 45.^[3][10] The form also asks nothing about diabetes, so a person with type 2 diabetes and heart disease is not shut out of this route by its text.^[3] For a person with diabetes, the diabetes route is usually simpler anyway.

The tablet form of Wegovy can be requested on the same form, and both versions must reach a set maintenance dose: 1.7 or 2.4 mg a week for the injection, 25 mg a day for the tablet, with up to eight weeks at each step on the way.^[3]

Does Iowa Medicaid cover Zepbound for sleep apnea?

Yes. Zepbound is preferred for moderate to severe obstructive sleep apnea when the baseline BMI is at least 30 and a lab or home sleep study from the past three years shows an apnea-hypopnea index (AHI) of 15 or above.^[3] The patient must meet the FDA’s age for this use, which the label limits to adults with obesity.^[3][11] The form has no CPAP step and does not require a sleep specialist.^[3]

The three-year window for the sleep study is generous, since several states want a test from the past year. Zepbound must reach a maintenance dose of 10 to 15 mg within 20 weeks, and renewals ask for documentation that the treatment is working.^[3] Our guide to Zepbound for sleep apnea covers the trials behind the indication.

What does Iowa require for Wegovy and MASH?

Proof of the fibrosis stage. The adult must have noncirrhotic MASH with F2 to F3 fibrosis, confirmed by a FibroScan reading of 8 to 15 kPa, a magnetic resonance elastography reading of 3.1 to 4.4 kPa, or a liver biopsy with an activity score of 4 or more.^[3] The patient cannot have had heavy alcohol use in the past year, defined as more than 20 grams a day for women or 30 grams for men.^[3]

Iowa considers Wegovy together with Rezdiffra, the other MASH drug, only after each has been tried alone at a full dose without enough response.^[3] Renewals need evidence of benefit, such as stable or better fibrosis or lower liver enzymes, and no progression to cirrhosis.^[3] The label notes that this use rests on accelerated approval.^[10] Our review of GLP-1s for MASH covers the trial, and our comparison of Rezdiffra and semaglutide explains the choice between them.

How do you file and renew an Iowa request?

The prescriber faxes form 470-0058 to 1-800-574-2515; the provider help desk is 1-877-776-1567.^[3] From December 1, 2026, Optum Rx reviews these requests for managed care members as well, and that help desk number is the one Iowa lists for its pharmacy prior authorization line.^[15] All three uses also require that the patient pair the drug with diet and activity changes and not take a second GLP-1.^[3] Once the patient reaches a maintenance dose, continuation requests are reviewed at 12-month intervals.^[2]

How do you appeal an Iowa Medicaid denial?

Check the reason first. A missing BMI date, sleep study or fibrosis result can often be fixed by sending the record again, but a request for weight loss alone has no route to win.^[2] Iowa’s Department of Health and Human Services lists a 90-day window to appeal a Medicaid decision, and its appeals line is 1-888-723-9637.^[6]

If a managed care plan denied the request, which applies to requests the plans decide through November 30, 2026, federal rules apply first. A plan member has 60 days from the plan’s denial notice to file an appeal with the plan, then 90 days or more after the plan decides to ask the state for a fair hearing.^[7][8] Iowa’s notice on the December 1 change does not say how appeals of Optum Rx decisions will work, so follow the route and deadline printed on your denial notice.^[15] Our walkthrough of prior authorization and appeals covers what to include, and the Iowa state page summarizes the Medicaid facts.

What if Iowa Medicaid will not pay?

Paying cash is the usual fallback, and Lilly’s savings card terms exclude anyone in Medicaid.^[13] In the prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, while Lilly charges $299 for the 2.5 mg starting dose, $399 at 5 mg and $449 at 7.5 mg and up when each refill comes within 45 days.^[13][14] Read each program’s rules on government coverage before you sign up. We compare these offers in our roundup of ways to pay less for a GLP-1 without coverage.